Categories: CancerNews

Correction: Cantargia Publishes Half-Year Report 2024

Correction of sign on three values in the Changes in working capital on page 16 of the report. Corrected values are; i) Changes in other current liabilites KSEK 1,056 and ii) total Changes in working capital KSEK 3,438, both related to Q2 2024, and iii) Change in receivables KSEK 645 for Q2 2023.

LUND, SWEDEN / ACCESSWIRE / August 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for January to June 2024.

“It has been an exciting and eventful period for Cantargia. With two projects in clinical phase where we are generating significant results, we have several important milestones ahead that will greatly influence the direction of our next steps. During this period, we have also had several productive discussions with external partners, which have provided valuable feedback. The conclusions are that we have results that generate interest, and it is important that we continue to invest our resources in cost-effective and value-enhancing activities” said Göran Forsberg, CEO of Cantargia.

News summary – Second quarter

  • The CAN10 project continued to pass important milestones and in June progress was reported in the Phase 1 clinical study, as seven dose groups had been treated without any safety issues. Moreover, analyses confirmed full receptor binding of CAN10 to the target IL1RAP on immune cells from the subjects. In addition to the clinical advances, the project announced three scientific publications.

  • In the oncology project, nadunolimab, promising preclinical results on the antibody’s unique anti-fibrotic effects on pancreatic cancer (PDAC) were presented. Furthermore, positive clinical results around nadunolimab’s role in prevention of neuropathy were communicated. A third presentation highlighted the importance of tumor-driving KRAS mutations and its correlation with nadunolimab’s mechanism of action.

  • The appeal brought against one of Cantargia’s granted European patents was withdrawn. Thereby, the patent remains in force.

  • The organization was strengthened through the recruitment of Ton Berkien as Chief Business Officer.

News – After the second quarter

Financial information

First half 2024 (1 Jan 2024 – 30 Jun 2024)

  • Net sales: SEK 0.0 M (0.0)

  • Operating loss: SEK -85.5 M (-140.2)

  • Loss after tax: SEK -80.2 M (-132.3)

  • Loss per share: before and after dilution, SEK -0.44 (-0.79)

  • Equity/assets ratio: 74 (76) per cent

  • Cash and cash equivalents: SEK 84.7 M (158.9)

  • Short-term investments: SEK 20.0 M (128.3)

Second quarter 2024 (1 Apr 2024 – 30 Jun 2024)

  • Net sales: SEK 0.0 M (0.0)

  • Operating loss: SEK -43.8 M (-62.6)

  • Loss after tax: SEK -43.3 M (-56.4)

  • Loss per share, before and after dilution: SEK -0.24 (-0.34)

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 28, at 3:00 p.m. CEST, where Cantargia’s CEO, Göran Forsberg, and CFO, Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: https://ir.financialhearings.com/cantargia-q2-report-2024.

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: https://conference.financialhearings.com/teleconference/?id=50048869.

The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-28 12:25 CEST.

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

Attachments
Interim Report Q2 2024 08 28

SOURCE: Cantargia

View the original press release on accesswire.com

Staff

Recent Posts

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension…

18 hours ago

Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX:…

18 hours ago

Avricore Grants Options

VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the…

18 hours ago

Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to October 3, 2024

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC,…

18 hours ago

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline…

18 hours ago

Jushi Holdings Inc. Announces Filing of Canadian Preliminary Base Shelf Prospectus

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…

18 hours ago